Data from FDA - Curated by Toby Galbraith - Last updated 21 April 2017

Licensing authority

FDA (Food and Drug Administration, USA)


Berinert is a plasma-derived C1 Esterase Inhibitor (Human) indicated for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) in adult and adolescent patients (1).

The safety and efficacy of Berinert for prophylactic therapy have not been established (1).

Full Prescribing information

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Visit Oral Anticoagulation Reversal


See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more.

Visit Psoriasis

Related Content

Advisory information


• Do not use in patients with a history of life-threatening immediate hypersensitivity reactions, including anaphylaxis, to C1 esterase inhibitor preparations (4).

Special warnings and precautions

• Hypersensitivity reactions may occur. Epinephrine should be immediately available to treat any acute severe hypersensitivity reactions following discontinuation of administration (5.1).
• Serious arterial and venous thromboembolic (TE) events have been reported at the recommended dose of C1 Esterase Inhibitor (Human) products, including Berinert, following administration in patients with HAE. Risk factors may include the presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives or certain androgens, morbid obesity, and immobility. Benefits of treatment of HAE attacks should be weighed against the risks of TE in patients with underlying risk factors. Monitor patients with known risk factors for TE events during and after Berinert administration.
TE events have been reported following administration of a C1 Esterase Inhibitor (Human) product when used off-label at higher than labeled doses.1 (5.2).
• Berinert is made from human plasma and may contain infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent (5.3).
• Laryngeal attacks: Following self-administration of Berinert for laryngeal attacks, advise patients to immediately seek medical attention (5.4).

Adverse reactions

• The most serious adverse reaction reported in subjects who received Berinert was an increase in the severity of pain associated with HAE (6.1).
• The most common adverse reaction reported in greater than 4% of the subjects and greater than placebo among subjects who received Berinert in the placebo-controlled clinical trial was dysgeusia (6.1).

Usage information

Dosing and administration
For intravenous use only.
• Store the vial in the original carton in order to protect from light. Store at 2-25°C (36-77°F). Do not freeze (2).
• Administer 20 International Units per kg body weight (2).
• Reconstitute Berinert prior to use using the Sterile Water for Injection, USP provided (2.1).
• Administer at room temperature within 8 hours of reconstitution (2.1).
• Inject at a rate of approximately 4 mL per minute (2.2).
• Do not mix Berinert with other medicinal products or solutions (2.2).
• Appropriately trained patients may self-administer upon recognition of an HAE attack (2.2).
Use in special populations
• Pregnancy: No animal data. Limited human data. Use only if clearly needed (8.1).
• Compared to adults, when adjusted for baseline, the half-life of Berinert was shorter and clearance (on per kg basis) was faster in children. The clinical implication of this difference is not known (12.3).

More information

Category Value
Authorisation number BLA125287
Orphan designation No
Product NDC 63833-825
Date First Approved 22-12-2011
Marketing authorisation holder CSL Behring GmbH